Gaboxadol was an experimental sleeping pill developed by Lundbeck and Merck. In March, 2007, Merck and H. Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a very different way than benzodiazepines and Z-drugs (zolpidem, zaleplon, etc). Lundbeck states that gaboxadol also increases deep sleep (stage 4).
See also
References
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
